Shares of Novavax are spiking in the after-hours after announcing top-line results of its Phase 2 clinical trial of NanoFlu. The trial compared the safety and immune responses of various quadrivalent formulations of NanoFlu, with or without Novavax' Matrix-M adjuvant, with two U.S.-licensed influenza vaccines in 1,375 healthy adults 65 years of age and older. Shares are currentlu up 9.5% in after-hours trading to $2.23 per share.
https://thefly.com/landingPageNews.php?id=2843511
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.